KALA
Kala Pharmaceuticals Inc
NASDAQ: KALA · HEALTHCARE · BIOTECHNOLOGY
$0.11
-3.93% today
Updated 2026-04-30
Market cap
$110.98M
P/E ratio
—
P/S ratio
23.75x
EPS (TTM)
$-3.31
Dividend yield
—
52W range
$0 – $21
Volume
9.1M
Kala Pharmaceuticals Inc (KALA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50000.00 | $455000.00 | $45000.00 | $0.00 | $0.00 | $0.00 | $6.07M | $6.36M | $11.24M | $3.89M | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | +810.0% | -90.1% | -100.0% | — | — | — | +4.7% | +76.7% | -65.4% | -100.0% | — | — |
| Cost of revenue | $50000.00 | $455000.00 | $15.66M | $297000.00 | $643000.00 | $955000.00 | $2.85M | $3.17M | $4.10M | $2.56M | $303000.00 | $259000.00 | $317000.00 |
| Gross profit | — | $-13.40M | $45000.00 | $-297000.00 | $-643000.00 | $-955000.00 | $3.23M | $3.19M | $7.14M | $1.33M | $-303000.00 | $-259000.00 | $-317000.00 |
| Gross margin | 0.0% | -2945.9% | 100.0% | — | — | — | 53.1% | 50.1% | 63.5% | 34.2% | — | — | — |
| R&D | $7.73M | $13.86M | $11.38M | $25.03M | $29.01M | $29.29M | $26.96M | $18.35M | $11.52M | $17.65M | $18.59M | $21.84M | $18.46M |
| SG&A | — | $3.84M | $4.61M | $7.64M | $10.87M | $35.43M | $65.02M | $81.07M | $105.06M | $65.03M | $21.77M | $18.34M | $23.63M |
| Operating income | $-11.13M | $-17.84M | $-15.95M | $-32.67M | $-39.88M | $-64.72M | $-88.22M | $-96.23M | $-109.43M | $-81.36M | $-39.15M | $-40.43M | $-42.41M |
| Operating margin | -22264.0% | -3920.9% | -35435.6% | — | — | — | -1452.5% | -1512.6% | -973.6% | -2090.3% | — | — | — |
| EBITDA | $-10.93M | $-17.54M | $-15.62M | $-32.37M | $-39.23M | $-63.77M | $-85.61M | $-93.39M | $-107.17M | $-80.50M | $-38.85M | $-40.17M | $-42.09M |
| EBITDA margin | -21862.0% | -3855.4% | -34702.2% | — | — | — | -1409.4% | -1468.0% | -953.4% | -2068.2% | — | — | — |
| EBIT | $-11.13M | $-17.84M | $-15.95M | $-32.67M | $-39.88M | $-64.72M | $-88.22M | $-96.23M | $-109.43M | $-81.36M | $-39.15M | $-40.43M | $-42.41M |
| Interest expense | $191000.00 | $1.61M | $604000.00 | $767000.00 | $1.02M | $3.31M | $8.48M | $8.59M | $8.38M | $7.27M | $5.81M | $5.78M | $3.28M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-10.65M | $-19.36M | $-16.68M | $-33.17M | $-42.21M | $-66.74M | $-94.35M | $-104.33M | $-142.60M | $-44.82M | $-42.20M | $-38.51M | $-26.98M |
| Net income growth (YoY) | — | -81.7% | +13.8% | -98.8% | -27.3% | -58.1% | -41.4% | -10.6% | -36.7% | +68.6% | +5.9% | +8.7% | +29.9% |
| Profit margin | -21306.0% | -4255.2% | -37071.1% | — | — | — | -1553.3% | -1639.8% | -1268.7% | -1151.6% | — | — | — |